Tesamorelin is a synthetic analogue of the human hypothalamic Growth Hormone-Releasing Factor (hGRF). It is a 44 amino acid polypeptide that acts on growth hormone-producing cells.
Tesamorelin is a synthetic analogue of the human hypothalamic Growth Hormone-Releasing Factor (hGRF). It is a 44 amino acid polypeptide that acts on growth hormone-producing cells.
These peptides are freeze-dried, a process that not only extends shelf life but also preserves the purity and integrity of the peptides during storage. We do not use any fillers in this process.
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), with effects similar to GHRH and other GHRH analogues such as sermorelin, GRF (1-29), and CJC-1295. The addition of trans-3-hexanoic acid to tesamorelin enhances its stability in human plasma, thereby extending its half-life. Despite this longer half-life, tesamorelin, like CJC-1295, maintains the natural pulsatile release of growth hormone (GH) and consequently has fewer side effects compared to molecules that disrupt this normal pattern of GH secretion.
Tesamorelin is primarily used in the treatment of HIV-associated lipodystrophy, a condition characterized by abnormal fat accumulation, particularly in the abdomen, which is a common side effect of both HIV infection and antiretroviral therapy. The exact cause of lipodystrophy is not fully understood, but protease inhibitors, which are commonly used in HIV treatment, are believed to contribute significantly to its development[1].
Before the approval of tesamorelin in 2010, patients with lipodystrophy had limited treatment options, including diet changes, exercise, and a few ineffective medications. Surgery was often considered but proved to be complicated and ineffective. Tesamorelin, approved by the FDA specifically for HIV-associated lipodystrophy, has been shown to reduce abdominal fat by almost 20% in affected individuals[1]. Studies indicate that tesamorelin is roughly four times more effective in reducing fat than all other available therapies combined[2].
People living with HIV are at an increased risk of cardiovascular disease (CVD), partly due to abnormal fat accumulation and the effects of antiretroviral drugs. Preventing CVD in this population is considered a crucial medical priority, after ensuring effective antiretroviral therapy (HAART). Traditionally, statins have been the cornerstone of managing cardiovascular risks in HIV-positive individuals.
Recent research shows that, in addition to reducing lipodystrophy, tesamorelin also lowers triglyceride levels, total cholesterol, and non-HDL cholesterol in HIV-positive patients. A 15% reduction in visceral fat correlates with a 50 mg decrease in triglyceride levels[3], [4]. By reducing ectopic fat deposition (fat stored in tissues like the liver or around organs), tesamorelin helps lower inflammation, which in turn reduces CVD risk. Inflammation from fat deposits in areas such as the liver and heart is a known risk factor for CVD, and reducing this fat is beneficial in preventing cardiovascular complications.
Research has shown that HIV infection and HAART can lead to growth hormone (GH) deficiency. The pituitary gland may be altered by the infection, and approximately one-third of patients on HAART suffer from GH deficiency[5]. This may explain the high incidence of lipodystrophy among HIV-positive individuals and why tesamorelin is particularly effective in treating this condition. Compared to exogenous GH treatment, tesamorelin offers a safer and more efficient way to increase GH levels in these patients.
Peripheral nerve damage can result from various factors, including injury, diabetes, or surgical procedures. This damage often leads to significant problems with motor and sensory functions, but nerve regeneration is notoriously challenging. Recent research suggests that manipulating growth hormone levels may help promote the healing of peripheral nerve injuries[6]. Tesamorelin, being an FDA-approved peptide, is considered a leading candidate for treating such injuries due to its proven ability to improve tissue regeneration and healing.
Emerging evidence indicates that GHRH analogues like tesamorelin may have cognitive benefits, particularly for patients in the early stages of dementia. A large, randomized, double-blind, placebo-controlled study conducted at the University of Washington School of Medicine over 20 weeks showed that tesamorelin could enhance cognition in dementia patients. It is thought that tesamorelin increases levels of gamma-aminobutyric acid (GABA) in the brain while reducing myo-inositol (MI), both of which are linked to cognitive function[7]. These findings suggest a potential new use for tesamorelin in treating dementia, opening doors for further research into its broader therapeutic potential.
Tesamorelin has been shown to improve both executive function and verbal memory in individuals with mild cognitive impairment, suggesting its potential for managing early-stage dementia.
As an FDA-approved peptide, tesamorelin is widely studied in clinical research. It is being explored for its potential to reduce cardiovascular disease in HIV patients, promote healing of peripheral nerve injuries, and slow the progression of dementia. Clinical trials are currently underway in these areas.
Tesamorelin has demonstrated minimal side effects, high oral bioavailability, and excellent subcutaneous bioavailability in animal models. However, the dosage used in animal studies is not directly applicable to humans.
(Note: Tesamorelin is intended solely for educational and scientific research purposes and is not for human consumption. Only licensed researchers should purchase tesamorelin for research purposes.)
This article was researched, edited, and organized by Dr. Logan, M.D., who holds a doctorate from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
No COAs available for this product.
